RadD from Fusobacterium nucleatum engages NKp46 to promote antitumor cytotoxicity
eLife · 2026
DOI: 10.7554/elife.108439 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Ahmed Rishiq und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC)…. Hauptthemen laut MEDLINE: Natural Cytotoxicity Triggering Receptor 1, Fusobacterium nucleatum, Bacterial Proteins, Antigens, Ly. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation, Israeli Innovation Authority, Israel Cancer Research Fund.
Abstract (Originalsprache)
Fusobacterium nucleatum , a gram-negative bacterium implicated in periodontal disease, contributes to tumor progression in various cancers. Whether the presence of F. nucleatum inhibits tumor progression of some cancers is largely unknown. Here, we identify an interaction between F. nucleatum and the natural killer (NK) cell receptor NKp46. Analysis of TCGA datasets revealed that the co-occurrence of F. nucleatum and high NKp46 expression correlates with improved survival in head and neck cancers but not in colorectal cancers. Using binding assays, we demonstrate that both human NKp46 and its murine ortholog, Ncr1, directly recognize the fusobacterial adhesin RadD. Genetic deletion of radD or blockade of NKp46 significantly impaired NK cell-mediated cytotoxicity in vitro and promoted tumor-cell growth. In vivo, infection with F. nucleatum accelerated tumor progression, with an exacerbated effect observed in the absence of RadD or NKp46. These findings highlight RadD as a critical ligand for NKp46 and establish the NKp46–RadD axis as a key interface in host–microbe–tumor interactions, offering a novel target for immunotherapeutic intervention in cancer influenced by microbial factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University Hadassah Medical School, Jerusalem, Israel.
- Institute of Medical Microbiology and Hygiene, Medical Centre University of Freiburg, Freiburg, Germany.
- The Institute of Dental Sciences, The Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel.
- Section of Biosystems and Function, Division of Oral and Systemic Health Sciences, UCLA School of Dentistry, Los Angeles, United States.
ORCID-Profile: Ahmed Rishiq, Reem Bsoul, Gilad Bachrach, Ofer Mandelboim
Förderung
- Israel Science Foundation
- Israeli Innovation Authority
- Israel Cancer Research Fund
Zitieren
APA
Rishiq, A., Galaski, J., Bsoul, R., Liu, M., Darawshe, R., Lux, R., Bachrach, G., & Mandelboim, O. (2026). RadD from Fusobacterium nucleatum engages NKp46 to promote antitumor cytotoxicity. eLife. https://doi.org/10.7554/elife.108439
Vancouver
Rishiq A, Galaski J, Bsoul R, Liu M, Darawshe R, Lux R, et al. RadD from Fusobacterium nucleatum engages NKp46 to promote antitumor cytotoxicity. eLife. 2026. doi:10.7554/elife.108439
BibTeX
@article{Rishiq2026,
author = {Rishiq, Ahmed and Galaski, Johanna and Bsoul, Reem and Liu, Mingdong and Darawshe, Rema and Lux, Renate and Bachrach, Gilad and Mandelboim, Ofer},
title = {RadD from Fusobacterium nucleatum engages NKp46 to promote antitumor cytotoxicity},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.108439}
}
EUVIMED